New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 1, 2014
21:13 EDTTSROTESARO announces final results from three Phase 3 trials of rolapitant
TESARO announced that final results from three Phase 3 trials of rolapitant, an investigational neurokinin-1 receptor antagonist in development for the prevention of chemotherapy-induced nausea and vomiting, were presented at the American Society of Clinical Oncology, ASCO, annual meeting in Chicago. "We are very pleased with these pivotal data which, along with the previously conducted Phase 2 study, will form the basis of our New Drug Application submission to the U.S. Food and Drug Administration in mid-2014," said Mary Lynne Hedley, Ph.D., president of TESARO. "Additionally, we look forward to expanding our niraparib development program to include clinical trials in the small cell lung cancer and first line ovarian cancer settings."
News For TSRO From The Last 14 Days
Check below for free stories on TSRO the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 10, 2014
09:20 EDTTSROTESARO management to meet with Leerink
Subscribe for More Information
September 8, 2014
12:22 EDTTSROOPKO reports licensee TESARO submits NDA for Rolapitant
Subscribe for More Information
08:10 EDTTSROTESARO submits rolapitant NDA to FDA
TESARO announced that it has submitted the New Drug Application, or NDA, for oral rolapitant to the FDA. Rolapitant is an investigational neurokinin-1 receptor antagonist developed for the prevention of chemotherapy-induced nausea and vomiting.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use